IL20RB and neoplasm: The characteristic “inflammatory–stromal” tumor microenvironment observed in the high-ITH, high-risk subgroup, together with IL20RB-driven proliferative and invasive advantages at the clonal level, may jointly underlie the poor clinical outcomes in this population.